Bristol-Myers Squibb Company (TSX:BMY)
22.45
-0.30 (-1.32%)
Oct 21, 2026, 1:24 PM EDT
Bristol-Myers Squibb Company Employees
Bristol-Myers Squibb Company had 32,500 employees as of December 31, 2025. The number of employees decreased by 1,600 or 4.69% compared to the previous year.
Employees
32,500
Change (1Y)
-1,600
Growth (1Y)
-4.69%
Revenue / Employee
2.15M CAD
Profits / Employee
405.58K CAD
Market Cap
174.67B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 32,500 | -1,600 | -4.69% |
| Dec 31, 2024 | 34,100 | 0 | - |
| Dec 31, 2023 | 34,100 | -200 | -0.58% |
| Dec 31, 2022 | 34,300 | 2,100 | 6.52% |
| Dec 31, 2021 | 32,200 | 1,950 | 6.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Bristol-Myers Squibb Company News
- 2 days ago - Bristol Myers Squibb to Showcase Next-Generation Cancer Modalities and Leadership Across Solid Tumors at ESMO 2026 - Business Wire
- 8 days ago - Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industry - WSJ
- 8 days ago - FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban - Business Insider
- 8 days ago - ‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks - Market Watch
- 8 days ago - Bristol Phase 3 win underscores opportunity for GRI Bio, says H.C. Wainwright - TheFly
- 8 days ago - Bristol Myers price target lowered to $60 from $65 at Wells Fargo - TheFly
- 9 days ago - Bristol Myers price target raised to $76 from $73 at Jefferies - TheFly
- 9 days ago - RBC says Bristol Myers’ ALOFT-IPF efficacy ‘encouraging, but confounding’ - TheFly